Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Heart Failure
Search: search_blue_button Advanced Search
Published Online
on April 14, 2009

Circulation: Heart Failure. 2009
Published online before print April 14, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.806240
A more recent version of this article appeared on May 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
2/3/189    most recent
CIRCHEARTFAILURE.108.806240v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maurer, M. S.
Right arrow Articles by Burkhoff, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maurer, M. S.
Right arrow Articles by Burkhoff, D.
Related Collections
Right arrow Contractile function
Right arrow Other heart failure
Right arrow Congestive

Original Article

Mechanisms Underlying Improvements in Ejection Fraction with Carvedilol in Heart Failure

Mathew S. Maurer1; Jonathan D. Sackner-Bernstein2,3; Lyna El-Khoury Rumbarger1; Madeline Yushak1; Donald L. King1 and Daniel Burkhoff1

1 Columbia Presbyterian Medical Center, New York, NY;
2 Clinilabs Inc., New York, NY

3 E-mail: jonathansb{at}yahoo.com

Background—Reductions in heart rate (HR) with beta-blocker therapy have been associated with improvements in ejection fraction (EF). However, the relative contributions of HR reduction, positive inotropism, afterload reduction and reverse remodeling to improvements in EF are unknown.

Methods and Results—29 patients (63±12 years old) with NYHA II-III heart failure underwent serial measurements of LV volumes using three-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6 and 12 months after initiation of carvedilol. From these parameters, LV contractility (indexed by the end-systolic pressure-volume ratio), total peripheral resistance (TPR) and effective arterial elastance (Ea) were derived. Overall, EF increased by 7-percentage points after 6 months of therapy (from 25±9 to 32±9, p <0.0001). This change was due to an increase in stroke volume (p<0.001) with no significant change in end-diastolic volume (p=0.15). The EF change correlated with increased contractility, decreased HR and decreased TPR (p<0.003 in each case). In those patients whose EF increased at least 5 points, ~60% of the increase was due to HR reduction, ~30% was due to increased contractility and <20% was due to the decrease in TPR.

Conclusions—Decreased HR, improved chamber contractility and afterload reduction each contributed significantly to improved EF with carvedilol.

Key Words: contractility • heart failure • heart rate • vasodilation • ejection fraction




This article has been cited by other articles:


Home page
J Am Coll Cardiol ImgHome page
D. Burkhoff
Chasing the Elusive Pressure-Volume Relationships
J. Am. Coll. Cardiol. Img., November 1, 2009; 2(11): 1282 - 1284.
[Full Text] [PDF]